SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Jefferies Initiates Coverage On Calliditas Therapeutics with Buy Rating, Announces Price Target of $44

Jefferies analyst Maury Raycroft initiates coverage on Calliditas Therapeutics (NASDAQ:CALT) with a Buy rating and announces Price Target of $44.

Benzinga · -
Jefferies analyst Maury Raycroft initiates coverage on Calliditas Therapeutics (NASDAQ: CALT) with a Buy rating and announces Price Target of $44.